(Reuters) -Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed ...

Biotech company Metsera, which develops weight-loss drugs and is backed by ARCH Venture Partners, said on Monday that it is ...

Metsera is aiming to put its weight loss drug MET-097i, which boasts of a longer half-life, through Phase III trials.

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its ...

The GLP-1 IPO arena has been heating up for the past two years and Metsera’s ask is one the largest in recent history.

Metsera reports $156.26 million loss in first nine months of 2024 Proceeds from IPO to fund MET-097i clinical trials Weight-loss drug market projected to reach $150 billion by early 2030s Jan 10 ...

Weight loss was dose-dependent ... M.D., Chief Medical Officer of Metsera. “The powerful reductions in weight affirm our earlier studies. We are also excited by the emerging tolerability ...

New York obesity healthcare firm, Metsera, has unveiled positive topline ... Additionally, the company claims that the trials never saw a weight loss plateau indicating a potential for further ...

Metsera links GLP-1 drug to 11% weight loss after 12 weeks, teeing up trial of monthly dosing The rest of the IPO proceeds will go toward “working capital” and “other general corporate ...

Just as quickly, investors are losing their appetite for the trade. After a disappointing trial of a new Novo Nordisk drug last month and lower-than-expected sales figures from Eli Lilly for two ...